Niranjan Biswal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Niranjan Biswal has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Barath Jagadisan
Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, London, UK
3 shared publications - Kalyana Prabhakaran
Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), Madurai, Tamil Nadu, India.
3 shared publications Parameswaran Narayanan
Department of Pediatrics Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Pondicherry India
3 shared publications- Rangan Srinivasaraghavan
Developmental Pediatrics unit, Christian Medical College Hospital, Vellore, India
3 shared publications Akshaya Arun
Department of Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605006, India
2 shared publicationsAvinash Anantharaj
Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605006, India
2 shared publications
Latest Publications
- 28 July 2026
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 122, 103220
Profile of sexual abuse among child survivors attending a tertiary health care centre
- 28 July 2026
- Published by Elsevier in Journal of Forensic and Legal Medicine
- Vol. 122, 103220
Profile of sexual abuse among child survivors attending a tertiary health care centre
- 24 March 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93  (5) , 557
Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy: Authors’ Reply-2
- 24 March 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93  (5) , 557
Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy: Authors’ Reply-2
- 9 March 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93  (5) , 555
Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy: Authors’ Reply
- 9 March 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93  (5) , 555
Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy: Authors’ Reply
- Open Access
- 9 February 2026
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111  (8) , 697-702
Outcome of early short course corticosteroid therapy in severe community-acquired pneumonia: a randomised controlled trial
Objective To evaluate the efficacy and safety of adjunctive dexamethasone in children with severe community-acquired pneumonia (CAP). Design Double-blind, randomised, placebo-controlled trial. Setting Tertiary care hospital. Patients: Children aged 2 months to 15 years diagnosed with severe CAP. Intervention Participants were randomised to receive intravenous dexamethasone or placebo for 5 days, in addition to standard antimicrobial therapy. Main outcome measures The primary outcome was treatment failure at 72 hours. Secondary outcomes included radiographic progression, respiratory failure, need for ventilation, shock, mortality, length of hospital stay, 4-week readmission and inflammatory markers. Results 132 children were enrolled (66 per group). Treatment failure at 72 hours occurred in 25.8% in the dexamethasone group vs 60.6% in the placebo group (HR 0.32; 95% CI 0.18 to 0.57; p=0.001). Radiographic worsening was significantly lower in the dexamethasone group (22.7% vs 57.6%; OR 0.22; p=0.001), as was progression to respiratory failure (10.6% vs 31.8%; OR 0.25; p=0.004). No significant differences were observed in need for ventilation, development of shock, mortality, hospital stay or readmission rates. While the reduction in erythrocyte sedimentation rate (ESR) from baseline to 72 hours was greater in the dexamethasone group, absolute ESR values at 72 hours did not differ consistently between groups, whereas no significant differences were observed in high-sensitivity C reactive protein, interleukin (IL)-6, IL-8 or IL-10. Conclusions Dexamethasone as adjunctive therapy in severe paediatric CAP significantly reduced early treatment failure and systemic inflammation without increasing adverse outcomes. These findings support its consideration in the management of severe CAP in children. Trial registration number CTRI/2021/09/036799.
- 9 February 2026
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111  (8) , 697-702
Open AccessOutcome of early short course corticosteroid therapy in severe community-acquired pneumonia: a randomised controlled trial
Objective To evaluate the efficacy and safety of adjunctive dexamethasone in children with severe community-acquired pneumonia (CAP). Design Double-blind, randomised, placebo-controlled trial. Setting Tertiary care hospital. Patients: Children aged 2 months to 15 years diagnosed with severe CAP. Intervention Participants were randomised to receive intravenous dexamethasone or placebo for 5 days, in addition to standard antimicrobial therapy. Main outcome measures The primary outcome was treatment failure at 72 hours. Secondary outcomes included radiographic progression, respiratory failure, need for ventilation, shock, mortality, length of hospital stay, 4-week readmission and inflammatory markers. Results 132 children were enrolled (66 per group). Treatment failure at 72 hours occurred in 25.8% in the dexamethasone group vs 60.6% in the placebo group (HR 0.32; 95% CI 0.18 to 0.57; p=0.001). Radiographic worsening was significantly lower in the dexamethasone group (22.7% vs 57.6%; OR 0.22; p=0.001), as was progression to respiratory failure (10.6% vs 31.8%; OR 0.25; p=0.004). No significant differences were observed in need for ventilation, development of shock, mortality, hospital stay or readmission rates. While the reduction in erythrocyte sedimentation rate (ESR) from baseline to 72 hours was greater in the dexamethasone group, absolute ESR values at 72 hours did not differ consistently between groups, whereas no significant differences were observed in high-sensitivity C reactive protein, interleukin (IL)-6, IL-8 or IL-10. Conclusions Dexamethasone as adjunctive therapy in severe paediatric CAP significantly reduced early treatment failure and systemic inflammation without increasing adverse outcomes. These findings support its consideration in the management of severe CAP in children. Trial registration number CTRI/2021/09/036799.
- 23 January 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93  (4) , 369-375
Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy
Objectives To compare the efficacy of sodium valproate (VPA) and levetiracetam (LEV) as initial maintenance monotherapy in children with new-onset epilepsy. Methods This randomised controlled trial was conducted in tertiary pediatric epilepsy and neurology clinics. Children 2–18 y with new-onset epilepsy were enrolled as participants. Patients were prescribed VPA (n = 58) or LEV (n = 58) at 20 mg/kg/d in two doses with increments of 20 mg/kg/d to a maximum of 60 mg/kg/d (Maximum daily dose: VPA 2 g/d and LEV 3 g/d). Primary outcome was the proportion of patients who achieved seizure control for three consecutive months. Secondary outcomes included the proportion of patients who achieved a 50% reduction in seizures from baseline and those who developed side-effects. Results A total of 116 patients were analysed using intention-to-treat analysis. There was no difference in the primary outcome between LEV vs. VPA groups [58.6% vs. 65.5%; relative risk (RR) 0.89 (95% CI, 0.67–1.19), p = 0.444]. There was no difference in patients who achieved a 50% seizure reduction from baseline between the two groups (70.7% vs. 70.7%) and side-effect profile (32.8% vs. 46.6%, p = 0.128) other than median (IQR) weight gain (kg), which was significantly lower in the LEV group (1.35, 0.70–1.60) as compared to the VPA group (2.15, 1.40–2.60) (p < 0.001). One patient in the VPA group had Stevens-Johnson syndrome. No mortality occurred. Conclusions No difference was noted between sodium valproate and levetiracetam in seizure control. With a favorable side-effect profile, levetiracetam can be safely considered as initial maintenance monotherapy in children with new-onset epilepsy.
- 23 January 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93  (4) , 369-375
Randomised Controlled Trial on Sodium Valproate and Levetiracetam in Children with New-Onset Epilepsy
Objectives To compare the efficacy of sodium valproate (VPA) and levetiracetam (LEV) as initial maintenance monotherapy in children with new-onset epilepsy. Methods This randomised controlled trial was conducted in tertiary pediatric epilepsy and neurology clinics. Children 2–18 y with new-onset epilepsy were enrolled as participants. Patients were prescribed VPA (n = 58) or LEV (n = 58) at 20 mg/kg/d in two doses with increments of 20 mg/kg/d to a maximum of 60 mg/kg/d (Maximum daily dose: VPA 2 g/d and LEV 3 g/d). Primary outcome was the proportion of patients who achieved seizure control for three consecutive months. Secondary outcomes included the proportion of patients who achieved a 50% reduction in seizures from baseline and those who developed side-effects. Results A total of 116 patients were analysed using intention-to-treat analysis. There was no difference in the primary outcome between LEV vs. VPA groups [58.6% vs. 65.5%; relative risk (RR) 0.89 (95% CI, 0.67–1.19), p = 0.444]. There was no difference in patients who achieved a 50% seizure reduction from baseline between the two groups (70.7% vs. 70.7%) and side-effect profile (32.8% vs. 46.6%, p = 0.128) other than median (IQR) weight gain (kg), which was significantly lower in the LEV group (1.35, 0.70–1.60) as compared to the VPA group (2.15, 1.40–2.60) (p < 0.001). One patient in the VPA group had Stevens-Johnson syndrome. No mortality occurred. Conclusions No difference was noted between sodium valproate and levetiracetam in seizure control. With a favorable side-effect profile, levetiracetam can be safely considered as initial maintenance monotherapy in children with new-onset epilepsy.
- Open Access
- 23 October 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 92  (11) , 1241
A Rare Variant (p. Cys291Phe) in Lipoprotein Lipase Gene Presenting as Chronic Liver Disease in Two Siblings
- 23 October 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 92  (11) , 1241
Open AccessA Rare Variant (p. Cys291Phe) in Lipoprotein Lipase Gene Presenting as Chronic Liver Disease in Two Siblings
- 9 August 2025
- Published by Springer Nature in Indian Journal of Pediatrics
Acute Myocardial Infarction in an Adolescent: Authors’ Reply
- 9 August 2025
- Published by Springer Nature in Indian Journal of Pediatrics
Acute Myocardial Infarction in an Adolescent: Authors’ Reply
- 14 February 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 92  (4) , 452
Acute Myocardial Infarction in an Adolescent
- 14 February 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 92  (4) , 452
Acute Myocardial Infarction in an Adolescent
- Open Access
- 9 February 2024
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91  (8) , 865
An Unusual Manifestation of a Common Tropical Infection: Correspondence
- 9 February 2024
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 91  (8) , 865
Open AccessAn Unusual Manifestation of a Common Tropical Infection: Correspondence
- 1 February 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108  (2) , 275-277
Bacteriuria due to Typhoidal and Nontyphoidal Salmonella: A Report of Three Cases from South India
: Urinary tract infection (UTI) with Salmonella is uncommon, accounting for merely 0.01% to 0.1% of cases of UTIs. It is reported more frequently in the presence of predisposing factors such as structural abnormalities of the urinary tract or weakened immune system. We present a case series of three patients with Salmonella bacteriuria and their susceptibility patterns. All three patients had underlying urologic features such as neurogenic bladder, chronic kidney disease, and urethral stricture, and two presented with urinary tract involvement symptoms.
- 1 February 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108  (2) , 275-277
Bacteriuria due to Typhoidal and Nontyphoidal Salmonella: A Report of Three Cases from South India
: Urinary tract infection (UTI) with Salmonella is uncommon, accounting for merely 0.01% to 0.1% of cases of UTIs. It is reported more frequently in the presence of predisposing factors such as structural abnormalities of the urinary tract or weakened immune system. We present a case series of three patients with Salmonella bacteriuria and their susceptibility patterns. All three patients had underlying urologic features such as neurogenic bladder, chronic kidney disease, and urethral stricture, and two presented with urinary tract involvement symptoms.